Fresh analysis reveals that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt conventional lifestyle plans.
Findings released in a leading health publication points out that while obese people often shed a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users purchasing these treatments should be informed of the danger of fast weight regain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a return to original mass within about 18 months.
Weighing Approaches
The study, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers note that people who shed pounds through diet and exercise usually experience a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Experts suggest the mechanism of the drugs explains the accelerated rebound.
The injections mimic a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, due to the likelihood of weight regain, the therapy should be considered life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "underscore the long-term nature of excess weight," comparing it to managing conditions like hypertension.
User Experiences
Individuals who have come off the medication report a intense resurgence of hunger.
"It felt as if a switch that goes on and I was suddenly starving," described a patient.
The struggle is worsened if individuals have not established lasting lifestyle or habit modifications during therapy.
Growing Interest
Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Use is greater among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while the jabs are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on integrated lifestyle changes.
